How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

254 results for

Alpha-Hydroxy acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging

dermatitis on the face, rosacea, allergic rhinitis, herpes Known hypersensitivity Previous Keloids Laser ablative procedures within the last one month Chemical Peels in the last 6 months Used oral retinoids in the last 6 months Used topical retinoids in the past one week Used Scrub, Alpha Hydroxy Acid, skin irritant for the past 24h Presence of facial warts, fungal infections Photoallergies Prior poor reaction to a chemical peel Radiotherapy Skin type V and VI Contacts and Locations Go to Information (...) The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2014 Clinical Trials

22. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. (Abstract)

. To date, there are no clinical studies in the literature regarding the efficacy of hydroxyacids for psoriasis treatment.To evaluate the therapeutic efficacy of topical 20% alpha-hydroxy/polyhydroxy acid versus standard salicylic acid to reduce scaling in patients with moderate, chronic psoriasis.Twenty-five subjects with moderate, chronic psoriasis were enrolled in a 2-week, double-blind, left-right, randomized, bilateral comparison clinical trial to compare the efficacy of 20% alpha-hydroxy (...) /polyhydroxy acid emollient versus 6% salicylic acid cream and 24 were randomized/completed. Clinical evaluations to assess the severity of psoriasis and scaling were performed using a 6-point scale prior to treatment, as well as following 1 and 2 weeks of therapy.Twenty-four participants completed the study. Both 20% alpha-hydroxy/polyhydroxy acid emollient and 6% salicylic acid cream were efficacious in reducing scale of psoriatic lesions. The topical 20% alpha-hydroxy/polyhydroxyacid reduced scaling

2013 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

23. Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

collected. Change From Baseline in Bile Acid Synthesis as Measured by Serum 7 Alpha-Hydroxy-4-Cholesten-3-One C4 Level [7 Alpha C4]) at Weeks 4, 8, 13, and Last Post -Baseline Visit (Week 13/ET) [ Time Frame: Baseline, Weeks 4, 8, 13 and Last Post-baseline Visit (Week 13/ET) ] C4 7 alpha-hydroxy-4-cholesten-3-one is an intermediate in the biochemical synthesis of bile acids from cholesterol and its concentrations reflect the activity of the bile acid synthetic pathway. Elevated levels of C4 indicate (...) Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2013 Clinical Trials

24. Effects of clofibrate on some microsomal hydroxylations involved in the formation and metabolism of bile acids in rat liver. Full Text available with Trip Pro

Effects of clofibrate on some microsomal hydroxylations involved in the formation and metabolism of bile acids in rat liver. 1. The liver microsomal metabolism of [4-14C]cholesterol, endogenous cholesterol, 7 alpha-hydroxy-4-[6 beta-3H]cholesten-3-one, 5-beta-[7 beta-3H]cholestane-3 alpha, 7 alpha-diol and [3H]lithocholic acid was studdied in control and clofibrate (ethyl p-chlorophenoxyisobutyrate)-treated rats. 2. The extent of 7 alpha-hydroxylation of exogenous [414C]cholesterol (...) and endogenous cholesterol, the latter determined with a mass fragmentographic technique, was the same in the two groups of rats. The extent of 12 alpha-hydroxylation of 7 alpha-hydroxy-4-cholesten-3-one and 5 beta-cholestane-3 alpha, 7 alpha-diol was increased by about 60 and 120% respectively by clofibrate treatment. The 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol was not significantly affected by clofibrate. The 6 beta-hydroxylation of lithocholic acid was about 80% higher

1976 Biochemical Journal

25. L-α-HYDROXY ACID OXIDASE ACTIVITY IN TETRAHYMENA : Change With Physiological State Full Text available with Trip Pro

L-α-HYDROXY ACID OXIDASE ACTIVITY IN TETRAHYMENA : Change With Physiological State 6057813 1968 01 14 2018 11 13 0021-9525 34 3 1967 Sep The Journal of cell biology J. Cell Biol. L-alpha-hydroxy acid oxidase activity in Tetrahymena. Change with physiological state. 911-5 Levy M R MR Hunt A E AE eng Journal Article United States J Cell Biol 0375356 0021-9525 0 Culture Media 9005-79-2 Glycogen EC 1.- Oxidoreductases IY9XDZ35W2 Glucose S88TT14065 Oxygen IM Animals Culture Media Glucose metabolism

1967 The Journal of cell biology

26. The oxidation of d-α-hydroxy acids in animal tissues Full Text available with Trip Pro

The oxidation of d-α-hydroxy acids in animal tissues 13922962 1998 11 01 2018 12 01 0264-6021 81 1961 Oct The Biochemical journal Biochem. J. The oxidation of D-alpha-hydroxy acids in animal tissues. 104-14 TUBBS P K PK GREVILLE G D GD eng Journal Article England Biochem J 2984726R 0264-6021 0 Acids 0 Carboxylic Acids 0 Hydroxy Acids EC 1.- Oxidoreductases OM Acids metabolism Animals Carboxylic Acids Hydroxy Acids Mitochondria metabolism Oxidation-Reduction Oxidoreductases metabolism ACIDS

1961 Biochemical Journal

27. Effects of inhibitors on mitochondrial d-α-hydroxy acid dehydrogenase Full Text available with Trip Pro

Effects of inhibitors on mitochondrial d-α-hydroxy acid dehydrogenase 13922963 1998 11 01 2018 12 01 0264-6021 82 1962 Jan The Biochemical journal Biochem. J. Effects of inhibitors on mitochondrial D-alpha-hydroxy acid dehydrogenase. 36-42 TUBBS P K PK eng Journal Article England Biochem J 2984726R 0264-6021 0 Hydroxy Acids EC 1.- Oxidoreductases EC 1.1.- Alcohol Oxidoreductases EC 1.1.99.6 D-2-hydroxyacid dehydrogenase OM Alcohol Oxidoreductases Hydroxy Acids Mitochondria metabolism

1962 Biochemical Journal

29. A 10% glycolic acid containing oil-in-water emulsion improves mild acne: a randomized double-blind placebo-controlled trial. (Abstract)

A 10% glycolic acid containing oil-in-water emulsion improves mild acne: a randomized double-blind placebo-controlled trial. Acne is characterized by hyperseborrhea, follicular hyperkeratosis, and growth of propionibacteria. Alpha hydroxy acids depending on the pH of the finished product exhibit comedolytic as well as antimicrobial properties.The aim of this study was to investigate an oil-in-water emulsion-containing 10% glycolic acid (pH 4; Dr. August Wolff GmbH & Co. KG Arzneimittel (...) and intention-to-treat analysis was the same. Acne improved significantly in the verum group up to day 90. Already at day 45, there was a statistical significant (5% level) difference against placebo. The subjective evaluation of the verum by physicians and patients regarding clinical efficacy and tolerability was favorable. Regarding reported adverse effects, there was no statistically significant difference (5% level) between verum and placebo.The 10% glycolic acid containing oil-in-water emulsion

2011 Journal of cosmetic dermatology Controlled trial quality: predicted high

30. EndolucinBeta - lutetium (177 Lu) chloride - radiolabelling

in the generation of 177 Ytterbium, which declines rapidly with a half-life of 1.9 h to 177 Lu. The chromatographic process to separate ytterbium from 177 Lu utilises alpha-hydroxy-isobutyric acid (HIBA, CAS no. 594 (...) . Product information 49 2.9.1. User consultation 49 Assessment report EMA/CHMP/404078/2016 Page 3/58 2.9.2. Labelling exemptions 49 2.9.3. Additional monitoring 50 3. Benefit-Risk Balance 50 4. Recommendations 51 References 53 Assessment report EMA/CHMP/404078/2016 Page 4/58 List of abbreviations ccRCC Clear cell renal cell carcinoma CT Computed tomography DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid DOTANOC [DOTA0-1-Nal3]octreotide DOTATATE [DOTA0,Tyr3]octreotate DOTATOC [DOTA0,Tyr3

2016 European Medicines Agency - EPARs

31. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

release; EWL = excess weight loss; FDA = Food and Drug Administration; FDG = 18F-fluorodeoxyglucose; GABA = gamma-aminobutyric acid; GERD = gastro- esophageal reflux disease; GI = gastrointestinal; GLP-1 = glucagon-like peptide 1; HADS = Hospital Anxiety and Depression Scale; HDL-c = high-density lipopro- tein cholesterol; HR = hazard ratio; HTN = hyperten- sion; HUNT = Nord-Trøndelag Health Study; ICSI = intracytoplasmic sperm injection; IFG = impaired fast- ing glucose; IGT = impaired glucose (...) prospective or case-controlled trials; MRI = magnetic resonance imaging; MUFA = monoun- saturated fatty acid; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis; NES = night eating syndrome; NHANES = National Health and Nutrition Examination Surveys; NHLBI = National Heart, Lung, and Blood Institute; NHS = Nurses’ Health Study; NICE = National Institute for Health and Care Excellence; OA = osteoarthritis; OGTT = oral glucose tolerance test; OR = odds ratio; OSA = obstructive

2016 American Association of Clinical Endocrinologists

32. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Full Text available with Trip Pro

compared to earlier stages of liver fibrosis. Patients with lean NAFLD had higher serum secondary BA and FGF19 levels and reduced 7-alpha-hydroxy-4-cholesten-3-one (C4) levels (P < 0.05 for all). These differences were more profound in early compared to advanced stages of fibrosis (P < 0.05 for both). Lean patients demonstrated an altered gut microbiota profile. Similar findings were demonstrated in lean and non-lean murine models of NAFLD. Treating mice with an apical sodium-dependent bile acid (...) Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset of patients are lean, but their underlying pathophysiology is not well understood. We investigated the role of bile acids (BAs) and the gut microbiome in the pathogenesis of lean NAFLD. BA and fibroblast growth factor 19 (FGF19) levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like

2019 Hepatology

33. Novel combination for the treatment of acne differentiated based on gender: a new step towards personalized treatment. (Abstract)

and Boswellia serrata were added, the oral supplement for females contains myo-inositol and folic acid. The topical cream device is represented by the association between active plant agents (verbascoside, Ocimum gratissimum) and keratolytic molecules (salicylic acid, gluconolactone, complex alpha-hydroxy acids).An equal number of male and female patients with mild to moderate acne were enrolled in a double-blinded clinical trial. Efficacy and tolerability evaluations were performed at week 4 (T1) and week

2018 Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia Controlled trial quality: uncertain

34. Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

. The participant has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study IP. Among these are use of the following: Topical glucocorticoids of potency greater than 2.5% hydrocortisone or desonide within the 30 days prior to the Screening Visit. Retinoids (such as etretinate, isotretinoin, acetretin, tazarotene, tretinoic acid, adapalene) systemically or topically, or >5% concentration of an alpha hydroxy acid (such as glycolic acid, lactic acid) within

2018 Clinical Trials

35. Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Therapy : 12 weeks Anthralin, bimatoprost, glucocorticosteroids, diphencyprone, diphenylcycloprophenone (DPCP), Squaric acid dibutyl ester (SADBE), minoxidil, pimecrolimus, tacrolimus: 4 weeks Topical treatments (prescription and over-the-counter) that contain retinoids, retinol, alpha hydroxy acids (e.g. glycolic, lactic acids) and beta hydroxy acids (e.g. salicylic acid) on and around the eyebrow area: 4 weeks Subject has a history of sensitivity to any of the ingredients in the study medication

2018 Clinical Trials

36. Efficacy and Safety of PiQo4 Device for Treatment of Melasma

damage to the hair follicles with possible loss of hair in the treatment area Laser or medium/deep chemical peel, or surgery, or filler treatments using collagen, hyaluronic acid, or any other material at area of treatment, within 6 months of initial treatment or during the course of the study. IPL or superficial chemical peel within the previous 1 month Topical therapy with retinoids, imiquimod, 5-fluorouracil, ingenol mebutate, diclofenac, alpha-hydroxy acids, or salicylic acids within the previous 1 (...) month. Currently using topical retinoid, hydroquinone or corticosteroid or whitening cream such as alpha arbutin, azelaic acid, kojic acid ascorbic acid or any cosmetics within 2 weeks Lightening oral medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), light-sensitive medication, or steroids in the last 6 months History of keloid scarring, hypertrophic scarring, or of abnormal wound healing. History of connective tissue diseases such as systemic lupus erythematosus or scleroderma

2018 Clinical Trials

37. Synthesis and Reactions of α-Hydroxyphosphonates Full Text available with Trip Pro

;-alkoxy-, or α-acyloxyphosphonates, respectively. The oxidation of hydroxyphosphonates leads to ketophosphonates. The hydroxy function at the α carbon atom of hydroxyphosphonates may be replaced by a halogen atom. α-Aminophosphonates formed in the nucleophilic substitution reaction of α-hydroxyphosphonates with primary or secondary amines are also potentially bioactive compounds. Another typical reaction is the base-catalyzed rearrangement of &alpha;-hydroxy-phosphonates (...) to phosphates. Hydrolysis of the ester function of hydroxyphosphonates leads to the corresponding phosphonic acids.

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

38. A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation

participation, as applicable. Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable, within 6 months of study participation. Use of topical medications on the face, such as antibiotics, benzoyl peroxide, retinoids (isotretinoin), corticosteroids, hydroquinone, or products containing dihydroxyacetone or alpha-hydroxy with concentration > 8%, within 1 month of participation. History of malignant tumors in the target area. Skin abnormalities in the target area, e.g., cuts, scrapes (...) purposes. Agree to not undergo any other procedure(s) for skin rejuvenation during the study, including but not limited to chemical peel, laser and light based device treatment, and home-use device treatment. Agree to not undergo any injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler during the study. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course

2018 Clinical Trials

39. Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Systemic or topical retinoids e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene Topical alpha-hydroxy acids e.g., glycolic acid, lactic acid Systemic or topical 5-fluorouracil or imiquimod to skin above the knees Patients who have not recovered from adverse events (> Grade 1) due to prior treatments Treatment with any other investigational agents Recent major surgery within 4 weeks prior to starting study treatment. Minor surgeries such as placement of vascular access

2018 Clinical Trials

40. Efficacy of a Nutritional Supplement on Skin Health in Generally Healthy Adults

participating in other facial clinical trials Individuals who have routinely used alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks of baseline visit or Retin-A®, Retin-A Micro®, Renova®, Differin®, Avita®, Tazorac®, or Soriatane® within one month of baseline visit or have taken Accutane® within one year of baseline visit. Individuals who have used Retinol in the last six months prior to baseline visit Individuals with inflammatory acne lesions (i.e., papules

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>